Loading
A phase 1 trial of Sapu003 (SAPU-003, everolimus Deciparticle) run by SAPU NANO (US) LLC, now recruiting.
Sapu003 in Advanced mTOR-sensitive Solid Tumors is a phase 1 interventional study registered as NCT07369505 by SAPU NANO (US) LLC, with 27 participants planned, started 2025-12-15. Conditions recorded: Breast Cancer Metastatic, Renal Cell Carcinoma (RCC), Neuroendocrine Tumors, Tuberous Sclerosis Complex (TSC) and Hepatocellular Carcinoma (HCC). Interventions recorded: Sapu003 and Exemestane 25 MG.
Shares Neuroendocrine tumours, Hepatocellular carcinoma and the tag pipeline.
Shares Renal cell carcinoma, Hepatocellular carcinoma and the tag pipeline.
Shares Renal cell carcinoma, Hepatocellular carcinoma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Neuroendocrine tumours, Renal cell carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Renal cell carcinoma, Hepatocellular carcinoma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Renal cell carcinoma, Hepatocellular carcinoma, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Hepatocellular carcinoma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/